An observational study in Angioplasty, Peripheral Arterial Disease and Drug-eluting Balloon, sponsored by iVascular S.L.U.. Recruiting at 15 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-11.
Sponsored by iVascular S.L.U. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Peripheral Arterial Disease with a site in France — 21 open to participants now, 27 under way, 4 of them phase 3. Peripheral Arterial Disease · France.
Among the 120 studies in Peripheral Arterial Disease with a site in France, this one is the 18th largest by planned enrollment of the 54 observational ones that give a count, is one of 11 that started in 2021, is one of 54 observational ones, reaches primary completion later than 0 of the 26 other live ones, and was the 84th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →21 of the 120 studies in Peripheral Arterial Disease with a site in France are open now. Recruiting first, the newest first:
Poitiers University Hospital · Sites in France
Ages 18+
Intervascular · Sites in France, United States, Belgium and 1 more country
Ages 18+
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Sites in France
Ages 18+
Eli Lilly and Company · Sites in France, United States, Argentina and 15 more countries
Ages 18+
Atrium Medical Corporation · Sites in France, United States
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 13 · Phase 4 7
First in 2002; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 106 across the 66 interventional studies, 298 across the 54 observational. Of the 82 that completed or were terminated, 12 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 120 have an industry lead sponsor. The 10 most frequent:
iVascular S.L.U. is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
iVascular S.L.U. has 3 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07283289Centre Hospitalier Intercommunal de Toulon La Seyne sur MerPrevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease | 2026-11 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
| NCT07322913IntervascularIntervascular Post-Market Clinical Follow-Up (PMCF) Registry | 2027-07 |
| NCT07181434Poitiers University HospitalImpact of Virtual Reality on Patient Pain During Lower Limb Revascularization Via Endovascular Surgery Under Local Anesthesia With Sedation | 2027-09-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 120 studies in Peripheral Arterial Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this all-comers registry is to explore the safety, efficacy, and cost-efficiency of the LUMINOR© DEB in de-novo and restenotic-FP lesions. For de-novo and restenotic lesions, especially for calcified and/or long lesions/occlusions, the use of debulking devices to improve recalibration and drug penetration will be evaluated in a specific sub-group.
Patients with peripheral artery disease due to occlusive lesions, stenosis of ingraguinal arteries and restenosis after previous angioplasty with/without stent in that sector.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: LUMINOR© Paclitaxel eluting balloon
Patients will be treated with the Luminor paclitaxel eluting balloon
Primary Endpoint Efficacy measured by presence of primary patency of the target lesion based on ultrasound images
Primary Patency is defined as Freedom from Clinically-Driven Target Lesion Revascularization and from Binary Restenosis.
Time frame: 12 Months
Overall Medical Safety
Combination assessment of freedom from all-cause peri-procedural (≤30 day) death and freedom at 3 years from the following: index limb amputation (above or below the ankle), and all-cause mortality (with a detailed analysis of cardiovascular (CV) and non-CV deaths). Success is defined as freedom from all specified events; failure is defined as one or more specified events occurrences.
Time frame: 36 Months
Secondary Endpoint Medical Safety: Major vascular complications
Major vascular complications will be counted: * Haematoma at access site \>5 cm * False aneurysm * AV fistula * Retroperitoneal bleeding * Peripheral ischemia/nerve injury * Any transfusion required will be reported as a vascular complication unless clinical indication clearly other than catheterization complication * Vascular surgical repair
Time frame: ≤30 days after index procedure
Secondary Endpoint Medical Safety: Composite Safety
Combination assessment of freedom from all-cause death and freedom from the following: index limb amputation (above or below the ankle = major or minor amputation) and index limb re-intervention. Success is freedom from all specified events; failure is occurrence of one or more specified events.
Time frame: 1, 6, 12, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: All-cause death
Death by any cause will be counted and stratified between CV and non-CV deaths. Cause of death will be analyzed to search for any specific increase of a death's subtype.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: Major amputation at target limb
Amputations above the ankle of the target leg will be counted. Optional histologic examination of fixed muscle segments in 10% neutral-buffered formalin could be performed in the Inserm unit 1034, Pessac, France to search for paclitaxel microparticle deposits, fibrinoid necrosis artery wall injury, inflammation, thrombus, hemorrhage, and fibrosis. Adjacent nonfixed samples of similar distal tissues, flash-frozen in liquid nitrogen, and retained at -80°C will be used for bioanalysis of paclitaxel levels by modified liquid chromatography/tandem mass spectroscopy.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: Minor amputation at target limb
Amputations below the ankle of the target leg will be counted.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: Target Vessel Revascularization (TVR)
Repeat intervention at the target vessel will be counted.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Medical Safety: Target Limb Reintervention
Repeat intervention at the target leg will be counted.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Acute Device Success
Device success is defined as, a per device basis, the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system. If a device is inserted into the subject but not used due to user error (e.g. inappropriate balloon length or transit time too long), this device will not be included in the device success assessment.
Time frame: During index procedure
Secondary Endpoint Efficacy: Technical Success
Technical Success of the balloon procedure is defined as successful access and deployment of the device and visual estimate of ≤ 30% diameter residual stenosis during the index procedure.
Time frame: During index procedure
Secondary Endpoint Efficacy: Procedural Success
Attainment of ≤ 30% residual stenosis in the treatment area without major adverse events (defined as occurrence of death, major amputation of the target limb, target vessel or distal revascularization) during the index procedure and through the hospital stay.
Time frame: Up to 30 days
Secondary Endpoint Efficacy: Primary Patency
Primary Patency is defined as Freedom from Clinically-Driven Target Lesion Revascularization and from Binary Restenosis. Binary restenosis is adjudicated by the validated center based on threshold Doppler PSVR ≥ 2.5 (together with waveform analysis \& color mosaic appearance) or based on angiographic ≥ 50% diameter stenosis (if angiography is performed although not required per protocol).
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Secondary Patency
Secondary Patency of the target lesion is defined as the absence of binary restenosis as adjudicated by the validated center, independent of whether or not patency is re-established via an endovascular procedure.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Clinically-driven Target Lesion Revascularization (TLR)
Revascularization of the target lesion with evidence of diameter stenosis \>50% determined by duplex ultrasound or angiography and new distal ischemic signs (worsening ABI or worsening Rutherford Category associated with the target limb or due to clinical symptoms).
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Target Lesion Revascularization (TLR)
A repeat revascularization procedure (percutaneous or surgical) of the original target lesion site.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Change of Rutherford classification from baseline
Patients are enrolled with a Rutherford grade of 2-5 for their target leg. The Rutherford scale is an indicator for the severity of Peripheral Vascular Disease: 0 = no symptoms, 6 = functional foot is no longer salvageable (leading to foot amputation).
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Change of resting Ankle Brachial Index (ABI) from baseline
The ABI values will be recorded and compared to the baseline values. The ABI is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. A ratio of 0.9-1.3 is in the normal range. Lower ratios indicate bad blood perfusion of the leg.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Change in Walking Impairment Questionnaire from baseline
The Walking Impairment Questionnaire values will be recorded and compared to the baseline values.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Efficacy: Change in quality of life from baseline, as measured by EQ-5D
The EQ-5D Questionnaire values will be recorded and compared to the baseline values.
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Secondary Endpoint Cost-Effectiveness (optional): factoring procedure and hospital admission costs
Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Jun 2022, 17 months after the start.
Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 17 months is below that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.